Rebecca Silbermann

3.2k total citations
59 papers, 1.1k citations indexed

About

Rebecca Silbermann is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Rebecca Silbermann has authored 59 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Hematology, 27 papers in Oncology and 25 papers in Molecular Biology. Recurrent topics in Rebecca Silbermann's work include Multiple Myeloma Research and Treatments (47 papers), Bone health and treatments (14 papers) and Protein Degradation and Inhibitors (12 papers). Rebecca Silbermann is often cited by papers focused on Multiple Myeloma Research and Treatments (47 papers), Bone health and treatments (14 papers) and Protein Degradation and Inhibitors (12 papers). Rebecca Silbermann collaborates with scholars based in United States, Italy and United Kingdom. Rebecca Silbermann's co-authors include G. David Roodman, Marc Tatar, Deborah L. Galson, Parameswaran Hari, G. David Roodman, Eva Medvedova, Kelly Godby, Saurabh Chhabra, Natalie S. Callander and Luciano J. Costa and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Rebecca Silbermann

54 papers receiving 1.1k citations

Peers

Countries citing papers authored by Rebecca Silbermann

Since Specialization

Citations

This map shows the geographic impact of Rebecca Silbermann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rebecca Silbermann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rebecca Silbermann more than expected).

Fields of papers citing papers by Rebecca Silbermann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rebecca Silbermann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rebecca Silbermann. The network helps show where Rebecca Silbermann may publish in the future.

Co-authorship network of co-authors of Rebecca Silbermann

This figure shows the co-authorship network connecting the top 25 collaborators of Rebecca Silbermann. A scholar is included among the top collaborators of Rebecca Silbermann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rebecca Silbermann. Rebecca Silbermann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Implications of MRD Progression in Newly Diagnosed Multiple Myeloma (NDMM) Treated with Quadruplet Therapy and Autologous Stem Cell Transplantation 2024 ·Blood ·Luciano J. Costa, Eva Medvedova, Binod Dhakal, Bhagirathbhai Dholaria, Smith Giri, (unknown), Susan Bal, Kelly Godby, (unknown), Rebecca Silbermann, Natalie S. Callander	1
2	Combination Regimens in MM Post Autologous Hematopoietic Cell Transplantation (AHCT) to Eliminate MRD Utilizing Iberdomide (COMMANDER): Results of Dose-Finding Component of a Phase 1b/2 Trial 2024 ·Blood ·Natalie S. Callander, (unknown), Rebecca Silbermann, Zhubin Gahvari, Eva Medvedova, Bhagirathbhai Dholaria, Naresh Bumma, Doris K. Hansen, (unknown), Pamela Hardwick, Luciano J. Costa	2
3	Phase 1b study of the anti-CD38 antibody mezagitamab in patients with relapsed/refractory multiple myeloma 2024 ·PubMed ·(unknown), Krina K. Patel, Meera Mohan, Sundar Jagannath, Rubén Niesvizky, Rebecca Silbermann, (unknown), (unknown), Scott R. McDonnell, Deborah Berg, Keith Stockerl‐Goldstein	0
4	Daratumumab Plus Lenalidomide (D-R) Versus Lenalidomide (R) Alone As Maintenance Therapy in Newly Diagnosed Multiple Myeloma (NDMM) after Transplant: Analysis of the Phase 3 Auriga Study Among Clinically Relevant Subgroups 2024 ·Blood ·(unknown), Larry D. Anderson, Alfred Chung, Chakra P. Chaulagain, (unknown), Andrew J. Cowan, (unknown), Sarah M. Larson, Douglas W. Sborov, Kenneth H. Shain, Rebecca Silbermann, (unknown), Maria Krevvata, Huiling Pei, Sharmila Patel, (unknown), Annelore Cortoos, Robin Carson, Thomas S. Lin, Ashraf Badros	1
5	Humoral immune reconstitution following therapy with daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara‐KRd), autologous hematopoietic cell transplantation, and measurable residual disease‐response‐adapted treatment cessation 2023 ·SHILAP Revista de lepidopterología ·Rebecca Silbermann, Timothy M. Schmidt, Susan Bal, Binod Dhakal, Bhagirathbhai Dholaria, (unknown), Saurabh Chhabra, Smith Giri, Kelly Godby, (unknown), Eva Medvedova, Robert F. Cornell, Natalie S. Callander, Luciano J. Costa	2
6	Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial 2023 ·The Lancet Haematology ·Luciano J. Costa, Saurabh Chhabra, Eva Medvedova, Bhagirathbhai Dholaria, Timothy M. Schmidt, Kelly Godby, Rebecca Silbermann, Binod Dhakal, Susan Bal, Smith Giri, Anita D’Souza, Aric C. Hall, Pamela Hardwick, James Omel, Robert F. Cornell, Parameswaran Hari, Natalie S. Callander	71
7	Outcomes of Hematopoietic Progenitor Cells Mobilization and Collection Following Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone Induction in Newly Diagnosed Multiple Myeloma 2021 ·Transplantation and Cellular Therapy ·Saurabh Chhabra, (unknown), Rebecca Silbermann, Bhagirathbhai Dholaria, Timothy M. Schmidt, Susan Bal, Luciano J. Costa, Bicky Thapa, Binod Dhakal, Anita D’Souza, Eva Medvedova, Parameswaran Hari, Natalie S. Callander	0
8	Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma 2021 ·Journal of Clinical Oncology ·Luciano J. Costa, Saurabh Chhabra, Eva Medvedova, Bhagirathbhai Dholaria, Timothy M. Schmidt, Kelly Godby, Rebecca Silbermann, Binod Dhakal, Susan Bal, Smith Giri, Anita D’Souza, Aric C. Hall, Pamela Hardwick, James Omel, Robert F. Cornell, Parameswaran Hari, Natalie S. Callander	146
9	Pericardial Tamponade and Other Cardiac Complications in POEMS Syndrome 2021 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), Sima S. Desai, (unknown), Chafic Karam, Rebecca Silbermann, Ahmad Masri	2
10	Second Autologous Stem Cell Transplant as Salvage in Multiple Myeloma – The Oregon Health and Science University Experience 2021 ·Clinical Lymphoma Myeloma & Leukemia ·(unknown), Staci Williamson, (unknown), Rebecca Silbermann, Eva Medvedova, Sarah Nagle, Levanto Schachter, Andy Chen, Emma C. Scott, Richard T. Maziarz	1
11	Untreated plasmacytoma of bone containing macroscopic intralesional fat and mimicking intraosseous lipoma: A case report and review of the literature 2020 ·Clinical Imaging ·Barry G. Hansford, Christopher J. Hanrahan, Nicole Girard, Rebecca Silbermann, Yoav Morag	1
12	Diagnosis of paraproteinemic neuropathy: Room for improvement 2020 ·Journal of the Neurological Sciences ·Chafic Karam, (unknown), Nizar Chahin, (unknown), Eva Medvedova, Rebecca Silbermann	5
13	EZH2 or HDAC1 Inhibition Reverses Multiple Myeloma-Induced Epigenetic Suppression of Osteoblast Differentiation 2017 ·PMC ·Juraj Adamik, Shunqian Jin, Quanhong Sun, Peng Zhang, Kurt R. Weiss, Judith L. Anderson, Rebecca Silbermann, G. David Roodman, Deborah L. Galson	1
14	Phase 2 Study of Carfilzomib and Bone Metabolism in Patients with Relapsed Multiple Myeloma 2017 ·Blood ·Attaya Suvannasankha, Rafat Abonour, Sherif S. Farag, Rebecca Silbermann, (unknown), (unknown), (unknown), Mark Tann, Sandra K. Althouse, Susan M. Perkins, G. David Roodman	4
15	Preclinical animal models of multiple myeloma 2016 ·BoneKEy Reports ·Seint T. Lwin, Claire M. Edwards, Rebecca Silbermann	34
16	Mechanisms of osteolytic and osteoblastic skeletal lesions 2015 ·BoneKEy Reports ·G. David Roodman, Rebecca Silbermann	57
17	Myeloma bone disease: Pathophysiology and management. 2013 ·PMC ·Rebecca Silbermann, G. David Roodman	7
18	Mechanisms of multiple myeloma bone disease 2012 ·BoneKEy Reports ·Deborah L. Galson, Rebecca Silbermann, G. David Roodman	39
19	Introduction to the Special Issue on The Microenvironment of Bone Metastasis 2011 ·Cancer Microenvironment ·Rebecca Silbermann	1
20	Engineering Mucosal RNA Interference in Vivo 2006 ·Molecular Therapy ·Yingjie Zhang, Patricia Cristofaro, Rebecca Silbermann, Oliver Pusch, Daniel Boden, Tamako Konkin, Virginia Hovanesian, (unknown), (unknown), Steven F. Moss, Bharat Ramratnam	74

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact